Tag Archives: Antibiotics

← Older posts

La Jolla Pharma Steps In With Better Offer, Wins Tetraphase Bidding War

It’s common for antibiotics developers to run into financial trouble these days but what’s unusual is seeing a bidding war erupt for one of them. The competition for Tetraphase Pharmaceuticals now has a new winner: La Jolla Pharmaceutical. San Diego-based La Jolla (NASDAQ: LJPC) has pledged to pay Tetraphase shareholders $43 million in cash now […]

Posted in Boston blog main, Boston top stories, National blog main, San Diego, San Diego blog main, San Diego top stories, San Francisco blog main | Tagged , , , , , , , , , , | Comments Off on La Jolla Pharma Steps In With Better Offer, Wins Tetraphase Bidding War

Antibiotic Development: HHS Not Yet Sold on “Pull” Incentives

The US Health and Human Services agency isn’t ready to go all in on “pull” incentives to encourage the development of new antibiotics, the agency indicated in response to a new Government Accountability Office report. “It is still unclear whether post-market financial incentives should necessarily be part of HHS’s forthcoming strategic framework to further incentivize […]

Posted in National, National blog main | Tagged , , , , , , , , , | Comments Off on Antibiotic Development: HHS Not Yet Sold on “Pull” Incentives

Why 2020 Is Pivotal for Microbiome Drug R&D (Or Maybe 2021, Given COVID-19)

The start of a potentially big biomedical breakthrough is blooming within all of us. Drug research aiming to turn bacteria into microbiome therapies now spans programs aiming to address gut disorders, autism, cancer, and more. Given the number of late-stage and mid-stage studies expected to report data in 2020—assuming they stay on track amid the […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Europe blog main, Europe top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Why 2020 Is Pivotal for Microbiome Drug R&D (Or Maybe 2021, Given COVID-19)

Forge Inks Roche Deal For Antibiotic Aimed at Drug-Resistant Infections

Forge Therapeutics has reached a deal with Roche to support development of an antibiotic for drug-resistant bacterial lung infections. The partnership announced this week gives the Swiss pharmaceutical giant the option to license the antibiotic from San Diego-based Forge. The preclinical biotech will retain control of the program, FG-LpxC LUNG, until Roche decides whether to […]

Posted in National blog main, San Diego, San Diego blog main, San Diego top stories | Tagged , , , , , , , , , , , , , , | Comments Off on Forge Inks Roche Deal For Antibiotic Aimed at Drug-Resistant Infections

Melinta’s Chapter 11 Auction Draws No Bids, Deerfield to Get Assets

The assets of Melinta Therapeutics will go to creditor Deerfield Management after no bidders for the company emerged, the antibiotics developer announced Wednesday. Under a court-approved Chapter 11 bankruptcy plan, any bids for the company were due by March 2. An auction was scheduled for March 6 in the event any bids were submitted. But […]

Posted in National blog main, New York, New York blog main, New York top stories | Tagged , , , , , , , , , , , , | Comments Off on Melinta’s Chapter 11 Auction Draws No Bids, Deerfield to Get Assets

Novo Holdings Repositions Antibiotics Funding Amid “Deteriorated” Market

Novo Holdings is repositioning the strategic focus of its REPAIR Fund in order to provide later-stage support to its portfolio companies, as the struggling antibiotics industry faces a dearth of investment. The Danish investor launched its REPAIR Impact Fund in 2018. An acronym for “Replenishing and Enabling the Pipeline for Anti-Infective Resistance,” the fund has […]

Posted in Europe, Europe blog main, National, National blog main | Tagged , , , , , , , | Comments Off on Novo Holdings Repositions Antibiotics Funding Amid “Deteriorated” Market

Amplyx Inks Novartis Deal for Another Compromised-Immune System Drug

Amplyx Pharmaceuticals, which is testing a new type of drug against life-threatening infections acquired by patients with compromised immune systems, has acquired the rights to another drug that could also be of use in treating those with limited ability to fight off sickness. On Monday, the clinical-stage San Diego biotech company announced it had added […]

Posted in National blog main, San Diego, San Diego blog main, San Diego top stories | Tagged , , , , , , , , , | Comments Off on Amplyx Inks Novartis Deal for Another Compromised-Immune System Drug

Four New Drugs Are Around the Corner. Here’s What You Need to Know.

[Updated, 3:40 pm ET, see below] The Food and Drug Administration approved 59 new drugs last year, a record for the agency which over the years has swung back and forth between tight control and leniency. We are in the midst of perhaps the agency’s most permissive era ever, thanks to its openness to speed […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Four New Drugs Are Around the Corner. Here’s What You Need to Know.

Ginkgo Eyes Antibiotics With Deal for Warp Drive’s Gene “Mining” Tech

Microbes designed by Ginkgo Bioworks are used in consumer products such as fragrances and beverages, and they’re undergoing research for applications in agriculture and medicine. The synthetic biology company has been pushing to expand its technology to more uses, and its latest deal moves the firm further into pharmaceutical research. Boston-based Ginkgo said Wednesday that […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, San Francisco blog main | Tagged , , , , , , , , , , , , , , , | Comments Off on Ginkgo Eyes Antibiotics With Deal for Warp Drive’s Gene “Mining” Tech

Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More

The road to every new drug approval is littered with the remains of earlier failures. Biopharmaceutical companies don’t like to talk about the failures. But it’s earnings season now, so some of them don’t have much choice. Biogen’s (NASDAQ: BIIB) earnings call this week was the first since its Alzheimer’s drug aducanumab failed in a Phase […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More← Older posts